Virtue Capital Management LLC Increases Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Virtue Capital Management LLC grew its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 4.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,208 shares of the company’s stock after purchasing an additional 981 shares during the period. Virtue Capital Management LLC’s holdings in Dyne Therapeutics were worth $834,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. FMR LLC lifted its stake in shares of Dyne Therapeutics by 69.7% in the third quarter. FMR LLC now owns 9,026,697 shares of the company’s stock valued at $324,239,000 after purchasing an additional 3,707,734 shares during the period. Janus Henderson Group PLC increased its holdings in Dyne Therapeutics by 47.3% in the third quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock valued at $244,755,000 after buying an additional 2,189,339 shares in the last quarter. State Street Corp lifted its position in shares of Dyne Therapeutics by 13.8% during the 3rd quarter. State Street Corp now owns 3,641,859 shares of the company’s stock valued at $130,816,000 after acquiring an additional 440,890 shares during the period. RTW Investments LP boosted its stake in shares of Dyne Therapeutics by 6.8% during the 3rd quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock worth $244,926,000 after acquiring an additional 431,503 shares in the last quarter. Finally, RA Capital Management L.P. grew its holdings in shares of Dyne Therapeutics by 5.5% in the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock worth $229,211,000 after acquiring an additional 331,940 shares during the period. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Stock Performance

Shares of NASDAQ DYN opened at $28.33 on Wednesday. The firm has a market cap of $2.88 billion, a P/E ratio of -7.96 and a beta of 1.09. Dyne Therapeutics, Inc. has a 1 year low of $10.33 and a 1 year high of $47.45. The firm’s 50 day moving average price is $30.85 and its 200 day moving average price is $35.36.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). As a group, equities analysts predict that Dyne Therapeutics, Inc. will post -3.45 EPS for the current year.

Insider Buying and Selling at Dyne Therapeutics

In other news, COO Susanna Gatti High sold 8,976 shares of Dyne Therapeutics stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $34.41, for a total value of $308,864.16. Following the transaction, the chief operating officer now directly owns 131,636 shares of the company’s stock, valued at $4,529,594.76. The trade was a 6.38 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Carlo Incerti sold 16,500 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $28.73, for a total transaction of $474,045.00. The disclosure for this sale can be found here. Insiders sold 176,257 shares of company stock worth $6,193,718 in the last 90 days. 20.77% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages recently issued reports on DYN. Oppenheimer reaffirmed an “outperform” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. Stifel Nicolaus lifted their price target on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Piper Sandler reissued an “overweight” rating and issued a $53.00 price objective on shares of Dyne Therapeutics in a research note on Monday, September 23rd. StockNews.com downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Finally, Royal Bank of Canada assumed coverage on shares of Dyne Therapeutics in a report on Tuesday, November 26th. They issued an “outperform” rating and a $45.00 price target on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $50.82.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.